|
|
Develops and markets products specializing in the application of the latest discoveries in cellular and molecular immunology and cancer biology to the development of proprietary therapeutics aimed at the treatment and eradication of cancer.
Web Address |
|
Phone |
604-331-0400 |
FAX |
604-331-0877 |
Contact |
Grant Atkins DIR/XCFO |
See Also: Historical Stats
See Also: Biotechnology Page
Other Company Info: Goldmood Company Index
Other Company Info: Main Menu
|
||||||
| Yahoo | Lycos | Fool | MSN | Nasdaq | OTC | Reuters |
| ClearStation | MarketWatch | Stockhouse | Edgar | TSX | SEC | |
For the nine months ended 30 September 2006, GeneMax Corporation's revenues totaled $0, down from $4K. Net loss increased 28% to $1M. Revenues reflect the absence of income due to the result of emphasis on the research and development of the TAP technologies. Higher Loss reflects lower operating margins, the presence of interest expense & licence fees, increased management fees & salaries and higher consulting fees.
